Point72 Asia Singapore Pte. Ltd. Sells 1,952 Shares of LivaNova PLC (NASDAQ:LIVN)

Point72 Asia Singapore Pte. Ltd. lowered its stake in LivaNova PLC (NASDAQ:LIVN) by 58.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,402 shares of the company’s stock after selling 1,952 shares during the quarter. Point72 Asia Singapore Pte. Ltd.’s holdings in LivaNova were worth $77,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in LIVN. Fifth Third Bancorp boosted its stake in shares of LivaNova by 97.1% in the 2nd quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock worth $37,000 after buying an additional 332 shares during the last quarter. Hexagon Capital Partners LLC increased its position in LivaNova by 117.8% during the second quarter. Hexagon Capital Partners LLC now owns 684 shares of the company’s stock valued at $37,000 after acquiring an additional 370 shares during the last quarter. Lazard Asset Management LLC bought a new position in LivaNova in the first quarter valued at about $84,000. Canada Pension Plan Investment Board purchased a new position in LivaNova in the second quarter worth about $88,000. Finally, Acadian Asset Management LLC bought a new stake in shares of LivaNova during the 1st quarter valued at about $94,000. Institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Robert W. Baird upgraded shares of LivaNova from a “neutral” rating to an “outperform” rating and increased their price objective for the stock from $55.00 to $66.00 in a research note on Tuesday, September 17th. Baird R W upgraded shares of LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 17th. Stifel Nicolaus boosted their price objective on shares of LivaNova from $70.00 to $72.00 and gave the company a “buy” rating in a research report on Thursday, July 25th. Finally, Needham & Company LLC raised their target price on LivaNova from $72.00 to $75.00 and gave the stock a “buy” rating in a report on Wednesday, July 31st. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, LivaNova presently has an average rating of “Buy” and a consensus target price of $70.80.

LivaNova Price Performance

Shares of NASDAQ:LIVN opened at $52.52 on Monday. The company has a market capitalization of $2.84 billion, a P/E ratio of -87.53 and a beta of 1.00. LivaNova PLC has a 1-year low of $42.75 and a 1-year high of $64.47. The firm’s 50 day simple moving average is $48.71 and its two-hundred day simple moving average is $53.34. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.45 and a quick ratio of 2.94.

LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, July 31st. The company reported $0.81 earnings per share for the quarter, beating analysts’ consensus estimates of $0.66 by $0.15. The company had revenue of $318.60 million for the quarter, compared to analysts’ expectations of $305.05 million. LivaNova had a negative net margin of 1.37% and a positive return on equity of 13.77%. Research analysts expect that LivaNova PLC will post 2.58 EPS for the current fiscal year.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.